12月5日 - ** 药物开发商Biomea Fusion BMEA.O股价盘前上涨3.4%至1.23美元
** 公司称实验性药物icovamenib有助于严重2型糖尿病患者在治疗9个月后更好地控制血糖
** 该公司在洛杉矶举行的世界胰岛素抵抗大会上介绍了这项研究
** BMEA 称，该药物旨在恢复胰岛素分泌细胞；在三种标准疗法失败的成人中进行了测试
** 公司表示，未发现严重副作用；计划今年晚些时候对 GLP-1 使用者进行进一步试验
** 截至上次收盘，该公司股价年累计下跌约 69
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.